Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Evaluation of GSH-generating prodrug via sulfonamide-induced “integrative” platform for selective cancer therapy

Abstract

A sulfonamide-appended gemcitabine prodrug was newly reported. The prodrug can efficiently distinguishing GSH from cysteine and homocysteine. Upon reaction with GSH that are relatively abundant in tumor cells, sulfonyl group cleavage occurs as well as active drug GMC release and concomitantly the innate fluorescence intensity increase. As a proof of concept, the colocalization experiments demonstrated that the probe LHX by receptor-mediated endocytosis bestowed significantly improved therapeutic efficacy and low side effects. Thus, these results suggest that the theranostic agent is promising “integrative” platform for efficient cancer therapy, which can be real-time activated that are not only selectively monitored and localized by specific tumour cells, but also undergo cascaded cleavage to induce both a fluorogenic response and release an active cytotoxic drug.

Back to tab navigation

Supplementary files

Article information


Submitted
31 Mar 2020
Accepted
18 May 2020
First published
19 May 2020

Analyst, 2020, Accepted Manuscript
Article type
Paper

Evaluation of GSH-generating prodrug via sulfonamide-induced “integrative” platform for selective cancer therapy

J. Liu and C. Cao, Analyst, 2020, Accepted Manuscript , DOI: 10.1039/D0AN00627K

Social activity

Search articles by author

Spotlight

Advertisements